Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

TRNI vs SMTI: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SMTI Wins Head-to-Head Institutional Verdict (4–0 across 6 Pillars · 7–1 Matrix Metrics)

SMTI Overall Winner 6-Pillar Tally: TRNI 0 – 4 SMTI (2 Tie) Matrix Metrics: TRNI 1 – 7 SMTI

As of Nov 20, 2026, Sanara MedTech Inc. (SMTI) is the stronger overall head-to-head candidate over TRNI (TRNI) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). TRNI carries a Unified Composite Score of 44.3/100 (HOLD) at $25.00 (N/M Forward P/E, N/A operating margin), whereas SMTI carries 51.4/100 (HOLD) at $32.55 (N/M Forward P/E, 7.2% operating margin).

  • Technical & Structure Timing Caution: TRNI is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 43.6); meanwhile SMTI trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TRNI vs SMTI
TRNI US Equity
TRNI
Institutional Equity
$25.00
-0.16% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.03β · 3% Vol
Unified Composite Score
44.3 / 100 HOLD
Tech 48.0 Fund 51.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -0.4%) with fading momentum, RSI 44
RSI-14: 43.6 · SMA20: $25.08 · SMA50: $25.05
SMTI NASDAQ Head-to-Head Winner
Sanara MedTech Inc. Common Stock
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$32.55
-0.37% 1D
Market Cap $300.0M
TTM Revenue $112M
Forward P/E N/M
Beta / 30D Vol 0.30β · 18% Vol
Unified Composite Score
51.4 / 100 HOLD
Tech 43.0 Fund 50.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 45.5 · SMA20: $32.40 · SMA50: $33.75

6-Pillar Scorecard Institutional Category Breakdown (TRNI 0 – 4 SMTI)

Columns: Metric · TRNI · SMTI
1. Valuation Multiples SMTI
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 2.7x
2. Growth & Scale SMTI
Revenue Growth (YoY) N/A +8.0%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A $112M
Market Cap N/A $300.0M
3. Profitability & Quality SMTI
Gross Margin N/A 93.0%
Operating Margin N/A 7.2%
Net Profit Margin N/A -2.7%
Return on Equity (ROE) N/A -34.9%
4. Balance Sheet & Cash Flow SMTI
Cash Generation (TTM) N/A $11M EBITDA
Cash Flow Margin N/A 9.4% EBITDA Mgn
Net Cash / Leverage N/A ROE $0.83 Book/Sh · -34.9% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Distribution NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Medical Instruments & Supplies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TRNI (1) vs SMTI (7)
Institutional Metric TRNI SMTI Criterion Row Edge
Market Capitalization
Scale
N/A $300.0M Larger Scale SMTI
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A +8.0% Higher Growth SMTI
Operating Margin (TTM)
Profitability
N/A 7.2% Higher Margin SMTI
Net Profit Margin
Profitability
N/A -2.7% Higher Margin SMTI
Return on Equity (ROE)
Capital Efficiency
N/A -34.9% Higher ROE SMTI
52-Week Range Position
Momentum
25% ($25–$25) 85% ($16–$36) Stronger Trend SMTI
Beta / 30D Volatility
Risk Regime
0.03β · 3% Vol 0.30β · 18% Vol Lower Realized Risk TRNI
Unified Institutional Score
Composite Signal
44.3 / 100 (HOLD) 51.4 / 100 (HOLD) Higher Composite SMTI
Trailing 12M Revenue (USD)
Operating Scale
N/A $112M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 93.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 2.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) $11M EBITDA ($0.83 Book/Sh · -34.9% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TRNI +1.04 pp
TRNI: +0.04% · SMTI: -1.0%
3M Horizon TRNI +3.98 pp
TRNI: -1.34% · SMTI: -5.32%
6M Horizon SMTI +26.87 pp
TRNI: -0.95% · SMTI: +25.92%
1Y Horizon SMTI +26.87 pp
TRNI: -0.95% · SMTI: +25.92%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TRNI vs SMTI. Trailing 12-month operating profitability (TRNI N/A vs SMTI 7.2%) and valuation multiples (TRNI N/M vs SMTI N/M Forward P/E) are benchmarked directly in Pillar 4 below.

TRNI ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
SMTI ADR TTM Benchmark FX-Normalized USD
TTM Revenue$112M
Gross Margin93.0%
Op. Margin7.2%
ROE / Fwd P/E-34.9% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TRNI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TRNI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SMTI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SMTI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TRNI Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SMTI Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $300.0M market capitalization and 7.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ TRNI vs SMTI Key Questions & Quantitative Answers

As of Nov 20, 2026, Sanara MedTech Inc. (SMTI) is the stronger overall head-to-head candidate over TRNI (TRNI) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). TRNI carries a Unified Composite Score of 44.3/100 (HOLD) at $25.00 (N/M Forward P/E, N/A operating margin), whereas SMTI carries 51.4/100 (HOLD) at $32.55 (N/M Forward P/E, 7.2% operating margin). Technical & Structure Timing Caution: TRNI is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 43.6); meanwhile SMTI trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SMTI leads the Growth & Scale pillar: TRNI posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with SMTI at +8.0% YoY revenue growth and +0.0% YoY earnings growth on $112M TTM revenue (93.0% gross margin, 7.2% operating margin). On trailing 12-month operating scale, TRNI generates N/A in USD-normalized revenue versus $112M for SMTI. In operating R&D and SG&A reinvestment, TRNI deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SMTI.

SMTI screens cheaper on headline valuation multiples. TRNI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas SMTI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 2.7x EV/Revenue (9.4% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TRNI (N/A ROE) versus SMTI (-34.9% ROE) capital efficiency.

In options market volatility and institutional positioning, TRNI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.03β · 3% Vol realized risk). By comparison, SMTI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.30β · 18% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.